// App-Quantinova.ai

SAT-300 : EFFECTS OF DAPAGLIFLOZIN AND DAPAGLIFLOZIN PLUS SAXAGLIPTIN ON HbA1c AND ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: PHASE II/III DELIGHT STUDY

Researchers

Presenter

  • C. Pollock

Principal Investigators

  • D.C. Wheeler

  • P. Rossing

  • D. Sjostrom

  • B. Stefansson

  • D. Reyner

  • A.M. Langkilde

  • H.J. Heerspink

Medical Centers

  • University of Copenhagen, Steno Diabetes Center Copenhagen, Copenhagen, Denmark

  • University of Groningen- university medical center Groningen, department of clinical pharmacy and pharmacology, Groningen, The Netherlands

  • AstraZeneca, Department of Cardiovascular and Metabolic Diseases- Global Medicines Development, Gothenburg, Sweden

  • AstraZeneca Research and Development, Gothenburg, Sweden

  • University College London, Division of Medicine, London, United Kingdom

  • Royal North Shore Hospital- University of Sydney, Department of Medicine, St Leonards, Australia

  • AstraZeneca, Gaithersburg, MD

Locations

  • Denmark

  • Sweden

  • United Kingdom

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Chronic kidney disease

  • Type 2 diabetes mellitus

  • Renal disease

  • Albuminuria

  • Diabetes

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Dapagliflozin

  • saxagliptin

  • Angiotensin II

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • II/III

Study Id's

  • NCT02547935

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved